Branding is the key image that we want to be known of
HEROSTEM® Inc., an innovation biotechnology company, is based in Shanghai, China. The laboratory initiated stem cell study and clinical applications back in 2007. Combining stem cell and genetic engineering platforms, HEROSTEM continues to deepen its research and development in the field of bio-based aesthetics, and has launched more than 20 regenerative aesthetic SKUs.
BETAGENE® Genetic, a Shanghai-based innovation-driven company and a subsidary of HEROSTEM®, is a global reagent and hydroxyapatite supllier. We provide and market a wide range of GMP recombinant proteins, enzymes, customized proteins and hydroxyapatite sphere through genetic engineering and biosynthesis . The company has developed several recombinant expression systems including bacterial, yeast, insects and mammalian.
Petal Regen Inc. focuses on the research and development of innovative medical aesthetic products. Petal is a joint venture established in 2023 by Derma Inc., Xiruiyan and BETAGENE Genetics. Petal focuses on dermal regeneration, rejuvenating and new material fillers. Agarose Filler, collagen filler, hydroxyapatite filler, PCL and PLLA fillers are the essential products of the company. Among them, Agarose Filler is the first product launched in China and has entered the clinical stage in 2024.
HEROSTEM JILIN was established in Changchun in 2012, a national high-tech enterprise focusing on the clinical research and application of stem cells. The company provides services such as umbilical cord and placental stem cell technology research and development and storage, stem cell culture, and cell drug research and development.
HEROSTEM CHENGDU was established in Chengdu, focusing on stem cell research and its application transformation. The company is committed to building the company into a first-class new stem cell technology operation center integrating clinical research and application, health detection and diagnosis, cell preparation and storage, science education and consultation.
